- In May 2026, Equifax and identity technology firm GBG expanded their partnership into the U.S., integrating Equifax Identity and Fraud solutions into GBG’s adaptive identity platform, GBG Go, while Equifax also agreed to adopt GBG’s data verification capabilities in the U.S. and globally.
- Equifax UK also partnered with Poland’s main credit bureau, Biuro Informacji Kredytowej, to extend access to its identity verification and fraud prevention tools, highlighting the company’s push to embed its data into core customer onboarding and security workflows across multiple regions.
- We’ll now examine how this broader integration of Equifax’s identity and fraud data into partner platforms may influence its investment narrative.
We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Equifax Investment Narrative Recap
To own Equifax, you need to believe its data, analytics and identity tools will stay embedded in essential financial and onboarding workflows, supporting consistent revenue and margin resilience. The recent GBG and BIK partnerships reinforce that integration theme but do not materially change near term catalysts or the main risks around litigation costs, regulatory scrutiny and revenue volatility in government and traditional lending.
Among recent updates, the launch of the Ataeva Product Suite in April 2026 is especially relevant here, as it also leans on Equifax data to help lenders optimize portfolios and customer acquisition. Together with the GBG and BIK collaborations, it illustrates how deeper product integration could support the long term thesis of expanding multi data solutions, even as competitive and regulatory pressures remain important watchpoints.
Yet against this backdrop, investors should be aware that growing regulatory focus on data privacy and historical breach issues could...
Read the full narrative on Equifax (it's free!)
Equifax's narrative projects $8.3 billion revenue and $1.3 billion earnings by 2029. This requires 9.7% yearly revenue growth and an earnings increase of about $0.6 billion from $698.7 million today.
Uncover how Equifax's forecasts yield a $229.19 fair value, a 32% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span roughly US$223.71 to US$390.01 per share, showing how far apart individual views can be. Set this against Equifax’s push to embed identity and fraud data into partner platforms and you can see why it helps to compare several different opinions before deciding how that expansion might affect the company’s longer term performance.
Explore 3 other fair value estimates on Equifax - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Equifax research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Equifax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Equifax's overall financial health at a glance.
No Opportunity In Equifax?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com